A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease

International Journal of Hematology

Volumn 91, Issue 3, 2010, Pages 464-470

  Onishi, Chie ^a   Ohashi, Kazuteru ^a   Sawada, Takeshi ^a   Nakano, Mikako ^a   Kobayashi, Takeshi ^a   Yamashita, Takuya ^a   Akiyama, Hideki ^a   Sakamaki, Hisashi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Allogeneic stem cell transplantation; Graft versus host disease; Infectious complication; Mycophenolate mofetil

Indexed keywords

CYCLOSPORIN; GANCICLOVIR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BRAIN DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HUMAN; HYPERTENSION; INFECTION; MALE; MYCOSIS; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMONIA; RETROPERITONEAL ABSCESS; SEPSIS; SKIN INFECTION;

ACUTE DISEASE; ADULT; ANEMIA, APLASTIC; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFECTION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77950917873     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0516-x     Document Type: Article

References (22)

1. RA Nash JH Antin C Karanes, et al. 2000 Phase 3 study comparing methotrexate and tacrolimus with methotorexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors Blood 96 2062 2068 1:CAS:528:DC%2BD3cXms1Chs7o%3D 10979948
2. HJ Deeg TP Loughran Jr R Storb, et al. 1985 Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone Transplantation 40 162 166 10.1097/00007890- 198508000-00011 1:STN:280:DyaL2M3ntlynsg%3D%3D 3895622 (Pubitemid 15007319)
3. K Ohashi Y Tanaka S Mori, et al. 2003 Low-dose antithymocyte globulin for treatment of steroid-pulse-resistant acute graft-versus-host disease Int J Hematol 77 99 102 10.1007/BF02982612 12568309 (Pubitemid 37127594)
4. N Basara MG Kiehl W Blau, et al. 2001 Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience Transplant Proc 33 2121 2123 10.1016/S0041-1345(01)01968-6 1:CAS:528:DC%2BD3MXjsleqs74%3D 11377471 (Pubitemid 33762653)
5. M Baudard A Vincent P Moreau, et al. 2002 Graft-versus-host disease mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients Bone Marrow Transplant 30 287 295 10.1038/sj.bmt.1703633 1:STN:280:DC%2BD38vltlShsA%3D%3D 12209350
6. A Busca F Locatelli F Marmont, et al. 2003 Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease Haematologica 88 837 839 12857569 (Pubitemid 36890123)
7. F Lopez P Parker A Nademanee, et al. 2005 Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease Biol Blood Marrow Transplant 11 307 313 10.1016/j.bbmt.2005.01.011 1:CAS:528:DC%2BD2MXktVOqt74%3D 15812396 (Pubitemid 40450758)
8. A Takami K Mochizuki H Okumura, et al. 2006 Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease Int J Hematol 83 80 85 10.1532/IJH97.05111 1:CAS:528:DC%2BD28Xhs1Cqtr0%3D 16443558 (Pubitemid 43172748)
9. Furlong T, Martin P, Flowers ME, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant. 2009 [Epub ahead of print].
10. E Racadot N Milpied P Bordigoni, et al. 1995 Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicentric pilot study including 15 patients Bone Marrow Transplant 15 669 677 1:STN:280:DyaK2MvgtVaiug%3D%3D 7670394
11. C Messina M Faraci V de Fazio, et al. 2008 Prevention and treatment of acute GvHD Bone Marrow Transplant 41 Suppl 2 S65 S70 10.1038/bmt.2008.57 1:CAS:528:DC%2BD1cXntVCnu7k%3D 18545247 (Pubitemid 351864710)
12. WA Lee L Gu AR Miksztal, et al. 1990 Bioavailability improvement of mycophenolic acid through amino ester derivatization Pharm Res 7 161 166 10.1023/A:1015828802490 1:CAS:528:DyaK3cXhs1CrtLY%3D 2308896 (Pubitemid 20208068)
13. EM Eugui SJ Almquist CD Muller, et al. 1991 Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion Scand J Immunol 33 161 173 10.1111/j.1365-3083.1991.tb03746.x 1:CAS:528:DyaK3MXit1Sqtb0%3D 1826793
14. M Jinta K Ohashi T Ohta, et al. 2007 Clinical features of allogeneic hematopoietic stem cell transplantation-associated organizing pneumonia Bone Marrow Transplant 40 465 472 10.1038/sj.bmt.1705768 1:STN:280: DC%2BD2svnvFSitg%3D%3D 17618318 (Pubitemid 47288227)
15. PA Rowlings D Przepiorka JP Klein, et al. 1997 IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade Br J Haematol 97 855 864 10.1046/j.1365-2141.1997.1112925.x 1:STN:280:DyaK2szmtVWlsw%3D%3D 9217189 (Pubitemid 27321388)
16. Ritter ML, Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis. 2009 [Epub ahead of print].
17. L Hambach M Stadler E Dammann, et al. 2002 Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation Bone Marrow Transplant 29 903 906 10.1038/sj.bmt.1703583 1:STN:280:DC%2BD38zjsleksg%3D%3D 12080355 (Pubitemid 34814698)
18. A Okamura M Yamamori M Shimoyama, et al. 2008 Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation Int J Hematol 88 104 110 10.1007/s12185-008-0093-4 1:CAS:528:DC%2BD1cXhtVOktb%2FI 18473127
19. A Busca EM Saroglia E Lanino, et al. 2000 Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation Bone Marrow Transplant 25 1067 1071 10.1038/sj.bmt.1702410 1:STN:280:DC%2BD3czptFyruw%3D%3D 10828867 (Pubitemid 30303596)
20. B Mookerjee V Altomonte G Vogelsang 1999 Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus Bone Marrow Transplant 24 517 520 10.1038/sj.bmt.1701936 1:STN:280: DyaK1MvhsVWisw%3D%3D 10482936 (Pubitemid 29423631)
21. Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group 1995 Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients Transplantation 60 225 232
22. N Basara WI Blau MG Kiehl, et al. 1998 Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient Transplant Proc 30 4087 4089 10.1016/S0041-1345(98)01351-7 1:CAS:528:DyaK1MXjtVemug%3D%3D 9865306 (Pubitemid 29013165)